People · Operator
Named in public records as an officer, director or promoter · active 2015–2025 · Biotechnology, Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Affinivax, Inc. | — | Biotechnology | Series D+ | $233.0M | $7.8B | 2021 |
| Corner Therapeutics, Inc. | — | Pharmaceuticals | Series C | $75.3M | $95.4M | 2025 |
| Platelet BioGenesis, Inc. | — | Other | Series B | $72.9M | $427.0M | 2021 |
| Ww International, Inc. | — | Other | Series B | $37.9M | $286.5M | 2015 |
| AsclepiX Therapeutics, Inc. | — | Biotechnology | Series A | $28.0M | $83.5M | 2023 |
Steven Altschuler at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Steven Altschuler on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steve Altschuler | 2 | 2 |
| Richard Malley | 2 | 2 |
| Chris Garabedian | 1 | 8 |
| Robert More | 1 | 7 |
| Philippe Amouyal | 1 | 6 |
| Peter Finn | 1 | 5 |
| Andrew Hack | 1 | 5 |
| Richard Murray | 1 | 5 |
| Mark McDade | 1 | 5 |
| Raymond Debbane | 1 | 4 |
| Alan Ezekowitz | 1 | 4 |
| Ben Askew | 1 | 3 |
| Jonathan Kagan | 1 | 3 |
| Jeffrey Karp | 1 | 3 |
| Amir Shojaei | 1 | 3 |
| Chidozie Ugwumba | 1 | 3 |
| GEORGE SIBER | 1 | 3 |
| Steven M. Altschuler | 1 | 3 |
| Sapna Srivastava | 1 | 3 |
| Andrew Bellinger | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.